• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

1.990 -0.020 (-1.00%)
Delayed Quote Updated: 3:56 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,529
Open 1.980
Bid (Size) 1.820 (500)
Ask (Size) 2.050 (400)
Prev. Close 2.010
Today's Range 1.920 - 2.000
52wk Range 1.870 - 4.939
Shares Outstanding 2,291,056
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
October 15, 2026
First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial... 
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
September 16, 2026
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune... 
From Xenetic Biosciences, Inc.
Via ACCESS Newswire

Performance

52-Week Range 59.7% below 52-week high
1.990
1.8752W Low 4.9452W High
1 Week 12.3% below 1-week high
1.891W Low 2.271W High

Xenetic Biosciences, Inc. - Common Stock (XBIO) traded between $1.87 and $4.94 over the past 52 weeks and last traded at $1.99, 59.7% below its 52-week high. Over the past week it ranged between $1.89 and $2.27.

Past 12 Months
-6.1%
-19.1%
-29.2%
-41.5%
-7.4%
-52.7%
1W -$0.13
1M -$0.47
3M -$0.82
6M -$1.41
YTD -$0.16
1Y -$2.22

XBIO was -52.7% over the past year, -41.5% over six months, -7.4% year to date, -6.1% in the last week.

12 Months vs Market
XBIO
-52.7%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months XBIO returned -52.7% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.20× 3-mo avg
Today 17,529 3-mo avg 88.0K
1W
25.1K
1M
87.1K
3M
88.0K
6M
52.5K
YTD
42.1K
1Y
45.4K

XBIO most recently traded 17,529 shares against a 3-month average daily volume of 88.0K.

More News

Read More
News headline image
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 07, 2026
From Xenetic Biosciences, Inc.
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 04, 2026
Via ACCESS Newswire
News headline image
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 01, 2026
Via ACCESS Newswire
News headline image
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026
Via ACCESS Newswire
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
February 11, 2026
Via Stocktwits
News headline image
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
November 19, 2025
Via Benzinga
News headline image
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025
Via ACCESS Newswire
News headline image
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025
Via ACCESS Newswire
News headline image
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges ↗
October 10, 2025
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
October 10, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
October 10, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
October 10, 2025
Via Chartmill
News headline image
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025
Via ACCESS Newswire
News headline image
4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings ↗
October 09, 2025
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
October 09, 2025
Via Chartmill
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
October 09, 2025
Via Benzinga
News headline image
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
October 08, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
October 08, 2025
Via Benzinga
News headline image
Nasdaq Gains 150 Points; US Mortgage Applications Decline ↗
October 08, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 08, 2025
Via Benzinga

Frequently Asked Questions

Is Xenetic Biosciences, Inc. - Common Stock publicly traded?
Yes, Xenetic Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Xenetic Biosciences, Inc. - Common Stock trade on?
Xenetic Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xenetic Biosciences, Inc. - Common Stock?
The ticker symbol for Xenetic Biosciences, Inc. - Common Stock is XBIO on the Nasdaq Stock Market
What is the current price of Xenetic Biosciences, Inc. - Common Stock?
The current price of Xenetic Biosciences, Inc. - Common Stock is 1.990
When was Xenetic Biosciences, Inc. - Common Stock last traded?
The last trade of Xenetic Biosciences, Inc. - Common Stock was at 10/16/26 03:56 PM ET
What is the market capitalization of Xenetic Biosciences, Inc. - Common Stock?
The market capitalization of Xenetic Biosciences, Inc. - Common Stock is 4.56M
How many shares of Xenetic Biosciences, Inc. - Common Stock are outstanding?
Xenetic Biosciences, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap